Incyte
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 2.5K
- Market Cap
- $12.6B
- Introduction
Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. The company was founded in April 1991 and is headquartered in Wilmington, DE.
A Dose Ranging Study of the Effect of Ruxolitinib Phosphate Cream When Applied to Participants With Plaque Psoriasis
- First Posted Date
- 2008-10-23
- Last Posted Date
- 2022-02-09
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 199
- Registration Number
- NCT00778700
Study to Determine the Safety and Efficacy of INCB018424 in Patients With Polycythemia Vera or Essential Thrombocythemia
- First Posted Date
- 2008-07-31
- Last Posted Date
- 2019-10-28
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 73
- Registration Number
- NCT00726232
Evaluate the Safety and Tolerability of INCB019602 When Administered With Metformin in Patients With Type 2 Diabetes
- First Posted Date
- 2008-06-17
- Last Posted Date
- 2012-10-30
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 48
- Registration Number
- NCT00698789
Safety and Efficacy of INCB013739 Plus Metformin Compared to Metformin Alone on Glycemic Control in Type 2 Diabetics
Phase 2
Completed
- Conditions
- Type 2 Diabetes
- Interventions
- First Posted Date
- 2008-06-17
- Last Posted Date
- 2018-02-14
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 302
- Registration Number
- NCT00698230
A Study to Determine the Effect and Safety of an Oral Janus Kinase 2 (JAK2)-Inhibitor (Ruxolitinib; INBC018424) in Patients With Multiple Myeloma
Phase 2
Completed
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2008-03-19
- Last Posted Date
- 2018-02-13
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 13
- Registration Number
- NCT00639002
Study of Ruxolitinib (INCB018424) Administered Orally to Patients With Androgen Independent Metastatic Prostate Cancer
- First Posted Date
- 2008-03-19
- Last Posted Date
- 2018-02-12
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 22
- Registration Number
- NCT00638378
Open Label, Safety and Efficacy Study of Topical Investigational Drug to Treat Patients With Psoriasis
- First Posted Date
- 2008-02-18
- Last Posted Date
- 2022-02-08
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 25
- Registration Number
- NCT00617994
A Study Exploring the Safety, Tolerability and Efficacy of a 4 Week Course of INCB018424 in Subjects With Active Rheumatoid Arthritis
- First Posted Date
- 2007-10-26
- Last Posted Date
- 2015-03-23
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 50
- Registration Number
- NCT00550043
Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis
Phase 1
Completed
- Conditions
- Polycythemia VeraThrombocytosisMyelofibrosis
- Interventions
- First Posted Date
- 2007-08-01
- Last Posted Date
- 2018-03-12
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 154
- Registration Number
- NCT00509899
Pharmacodynamic Study of the Effect of INCB013739 on Insulin Sensitivity in Obese, Type 2 Diabetic Subjects
Phase 2
Completed
- Conditions
- Diabetes Mellitus, Type 2Obesity
- Interventions
- Drug: Placebo
- First Posted Date
- 2007-05-24
- Last Posted Date
- 2016-12-06
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 24
- Registration Number
- NCT00478322
© Copyright 2025. All Rights Reserved by MedPath